[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maimonides Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":171},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,56,84,110,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100511439","impact-of-bright-light-therapy-on-prader-willi-syndrome-100511439",false,"NCT05939453","Impact of Bright Light Therapy on Prader-Willi Syndrome","A Randomized, Double-Blind, Controlled Trial of Bright Light Therapy on All-Cause Excessive Daytime Sleepiness in Prader-Willi Syndrome","PWS-LT","Inclusion Criteria:\n\n* Diagnosis of PWS confirmed by genetic testing\n* Score of 12 or above on the Epworth Sleepiness Scale (ESS).\n\nExclusion Criteria:\n\n* Subjects with an eye condition that could be negatively affected by bright light such as patients with a history of retinal damage or patients needing photosensitizing medications\n* A history of previous treatment with LT\n* Patients presenting with active psychosis or mania","ALL","6 Years","88 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a placebo controlled clinical trial to assess the utility of light therapy as a sufficient treatment for excessive daytime sleepiness in patients with Prader-Willi Syndrome",[28,29,30,31,32,33],"Prader-Willi Syndrome","Excessive Daytime Sleepiness","Hyperphagia","Body Weight","Mood","Behavior",[35,36,37,38,39,40,41,42],"Light Therapy","Aberrant Behavior Checklist","Clinical Global Impression- Improvement","Fitbit","Actigraphy reports","Epworth Sleepiness Scale","Hyperphagia Questionnaire (HQCT)","Modified Overt Aggression Scale (MOAS)","RECRUITING","2026-05-13",{"date":46,"type":47},"2026-05-15","ACTUAL",{"date":49,"type":47},"2023-10-01",{"date":51,"type":22},"2026-12",{"name":53,"class":54},"Maimonides Medical Center","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":55},"100632423","phase-4-pipelle-vs-the-curved-aspirator-device-100632423","NCT07513493","Pipelle vs the Curved Aspirator Device","The Conventional Pipelle vs the Curved Aspirator Device: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients \\\u003C18- 45 years with risk factors for endometrial cancer requiring endometrial biopsy.\n2. Patients ≥ 45 -95 years with abnormal uterine bleeding.\n3. Postmenopausal patients with bleeding or suspected endometrial pathology\n\nExclusion Criteria:\n\n1. Any patient who does not meet the inclusion criteria.\n2. Patients with contraindications to endometrial biopsy, including:\n\n   * Pregnancy\n   * Acute pelvic inflammatory disease\n   * Acute cervical infection\n   * Acute vaginal infection\n   * Cervical cancer\n   * Lack of patient consent",true,"FEMALE","18 Years","95 Years",{"count":68,"type":22},124,[70],"PHASE4","The primary aim of this study is to rigorously compare the efficacy of two commonly used endometrial sampling devices, the Pipelle and the Miltex, these devices are standard of care at Maimonides. This primary objective is critical, as the ability to accurately reach the uterine cavity is fundamental to obtaining adequate samples for histopathological evaluation, which is crucial for diagnosing endometrial cancer and other uterine pathologies.",[73],"Endometrial Biopsy",[75],"Gynecology","2026-03-30",{"date":78,"type":47},"2026-04-07",{"date":80,"type":47},"2026-01-02",{"date":82,"type":22},"2028-03-31",{"name":53,"class":54},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":64,"minAge":65,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":55},"100630783","phase-2-efficacy-of-cabergoline-in-inhibiting-lactation-and-alleviating-breast-symptoms-100630783","NCT07492160","Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant people aged 18 years or older\n* Gestational age between 12 and 18 weeks\n* Undergoing treatment for spontaneous or induced abortion at Maimonides Medical Center\n* Able to provide informed consent\n* Willing and able to complete study surveys\n\nExclusion Criteria:\n\n* Prior mastectomy\n* Currently breastfeeding\n* Current use of a dopamine agonist or dopamine antagonist medication\n* Known contraindication to Cabergoline according to the medication prescribing information",{"count":92,"type":22},348,[94],"PHASE2","The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are:\n\nDoes cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss?\n\nDoes cabergoline reduce the severity of breast symptoms and associated bother compared with placebo?\n\nResearchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss.\n\nParticipants will:\n\nComplete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure\n\nReceive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure\n\nComplete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother\n\nA subset of participants will provide blood samples at selected time points to measure serum prolactin levels",[97,98],"Pregnancy","Abortion",[100,101],"cabergoline","pregnancy","2026-03-19",{"date":104,"type":47},"2026-03-25",{"date":106,"type":47},"2026-03-16",{"date":108,"type":22},"2028-04",{"name":53,"class":54},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":63,"sex":17,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":130,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":55},"100522666","fibulink-syndesmosis-repair-system-with-early-full-weight-bearing-100522666","NCT06085586","Fibulink Syndesmosis Repair System With Early Full-Weight Bearing","Evaluation of Safety and Performance Outcomes of the Fibulink Syndesmosis Repair System With Early Full-Weight Bearing","Inclusion Criteria:\n\n* ankle fracture with syndesmotic disruption as assessed with intra-operative cotton test.\n\nThis includes the following injuries:\n\n* Syndesmotic sprain (without fractures)\n* Bimalleolar equivalent ankle fractures\n* Bimalleolar ankle fractures\n* Maisonneuve fractures\n* Trimalleolar ankle fractures without the need for posterior malleolus fixation\n* Ankle fracture dislocations\n\nExclusion Criteria:\n\n* 1\\) previous ankle surgery, 2) active local infection about the ankle, 3) chronic ankle deformity secondary to trauma or congenital, 4) ligamentous laxity, 5) pathologic fractures, 6) peripheral vascular disease, 7) peripheral neuropathy, 8) diabetes neuropathy and charcot, 9) open fractures, 10) poly trauma, 11) inability to provide informed consent, 12) symptomatic ankle osteoarthritis, 12) retained hardware, 13) pregnant, 14) metabolic bone disease, 15) history of chronic steroid use, 16) mal-reduced ankle fractures","22 Years",{"count":119,"type":22},56,[25],"The purpose of the study is to evaluate the ability of the Fibulink Syndesmosis Repair System to maintain reduction of the ankle syndesmosis. Appropriate reduction of the syndesmosis is critical due the changes in tibiotalar contact pressure observed in cadaveric studies.6,7 Malreduction and instability of the distal tibiotalar joint can lead to chronic instability, increased articular damage and ultimately degenerative arthritis.7,8 Medial to lateral translation of distal tibia and fibula of 2 mm or more has been considered pathologic.9 Earlier biomechanical study demonstrated the Fibulink system is superior in maintaining displacement of less than 2 mm.4 Given the improved strength, we also look to evaluate the outcomes of initiating full weight bearing (100%) with Controlled Ankle Motion (CAM) boot at 4 weeks postoperatively. One of the big limitations for trans-osseous screw fixation is delayed weight bearing due to risk of screw breakage.1 Suture button technique allowed for early weight bearing with average of 6 weeks postoperatively using TightRope.2,10-12By initiating full weight bearing (100%) with CAM boot at 4 weeks postoperatively, this would be a significant improvement in current clinical practice.",[123,124,125,126,127,128,129],"Ankle Fractures","Bimalleolar Fractures","Syndesmotic Injuries","Bimalleolar Equivalent Fracture","Maisonneuve Fracture","Trimalleolar Fractures","Ankle Dislocation",[123,124,126,128,131,125,132],"Maisonneuve Fractures","Ankle Dislocations","2026-03-17",{"date":135,"type":47},"2026-03-20",{"date":137,"type":47},"2023-07-13",{"date":139,"type":22},"2026-12-31",{"name":53,"class":54},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":63,"sex":64,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":170,"locationsCount":55},"100424514","phase-4-prevention-of-recurrent-uti-using-vaginal-testosterone-versus-placebo-placebo-100424514","NCT04807894","Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo","Prevention of Recurrent Urinary Tract Infection Using Vaginal Testosterone Versus Placebo","PIVoT","Inclusion Criteria:\n\n* 60-90 yo Female\n* Postmenopausal\n* Recurrent UTIs (three or more culture confirmed symptomatic episodes of UTI or two or more in the past 6 months).\n* English Proficiency\n* Unable or unwilling to use topical estrogen.\n* Patients with history of or current endometrial or breast cancer and current aromatase inhibitor therapy may also be included in study.\n* Patient on oral estrogen therapy may be included.\n* Patient with slings, prior vaginal surgery or pessary may be included.\n\nExclusion Criteria:\n\n* Current UTI\u002F Dipstick and culture positive (\\> trace leukocytes or nitrites)\n* Antibiotic (vaginal or oral) use in the last 4 weeks\n* Current sexually transmitted infection\n* Chronic Foley catheter use or chronic ureteral stent placement.\n* Vaginal probiotic use in the last 4 weeks\n* Patient currently using vaginal estrogen.\n* Post-void Residual Volume \\>150 mL or current diagnosis of urinary retention\n* Non-evaluated hematuria (\\> trace on dipstick, microscopic, gross)\n* Unable to complete study tasks or comply with follow up.","60 Years","90 Years",{"count":152,"type":22},100,[70],"Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract infections (UTI). This is believed to be due to hormonally induced changes in the vaginal flora associated with menopause. After menopause, there is a chemical changes in the vagina that may predispose to bacterial infections.\n\nThe role of vaginal estrogen creams to restore vaginal atrophy and prevent urinary tract infections has been well characterized. Vaginal testosterone (VT) application use in postmenopausal breast cancer patients on aromatase inhibitors have been shown to improve vaginal pH, vaginal atrophy symptom scores, dyspareunia, and vaginal dryness. Although testosterone has been used to improve sexual function in postmenopausal women, the effects of VT on vaginal flora and recurrent UTIs are unknown.\n\nThe purpose of this study is to determine whether topically applied vaginal testosterone cream is more effective than placebo in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections and to ascertain the effects of topical estrogen on the vaginal pH and flora.",[156,157,158],"Recurrent Urinary Tract Infection","Vaginal Atrophy","Postmenopausal Disorder",[160,161,162,163],"urinary tract infections,","postmenopausal women","vaginal atrophy,","vaginal flora","2025-11-04",{"date":166,"type":47},"2025-11-05",{"date":168,"type":47},"2020-11-01",{"date":139,"type":22},{"name":53,"class":54},""]